Anzeige
Erschienen in:
26.01.2017 | Kasuistiken
Adalimumab-induced pulmonary sarcoidosis not progressing upon treatment with etanercept
Erschienen in: Zeitschrift für Rheumatologie | Ausgabe 4/2017
Einloggen, um Zugang zu erhaltenAbstract
Tumor necrosis factor alpha (TNF-α) inhibitors effectively treat sarcoidosis, but can, paradoxically, induce sarcoidosis. The TNF-α inhibitor etanercept is most commonly associated with paradoxical sarcoidosis, which has previously been reported to be resolved by adalimumab. However, we describe the case of a patient with ankylosing spondylitis and adalimumab-induced sarcoidosis not aggravated by switching to etanercept, thus indicating that etanercept could be a treatment option for patients who develop paradoxical sarcoid-like reactions after treatment with other TNF-α inhibitors.